Ovarian cancer is the leading cause of death from gynecological cancers. Primary treatment
of advanced ovarian cancer (FIGO stages III and IV) until recently consisted of cytoreductive …

OBJECTIVE: To review the rationale for targeting the vascular endothelial growth factor
(VEGF), platelet-derived growth factor (PDGF), and fibroblast growth factor (FGF) pathways …

The introduction of new therapeutic agents into clinical practice of ovarian cancer, in
addition to the role of surgery and chemotherapy, has been the subject of numerous studies …

Despite an aggressive approach of surgical cytoreduction and adjuvant combination
chemotherapy, ovarian cancer mortality remains a significant problem. We are entering a …

Angiogenesis plays a pivotal role in normal ovarian physiology as well as in the formation
and progression of ovarian cancer. Several well-designed phase II and III trials studied the …

Data from preclinical and clinical studies reported in the last 2 years demonstrate the
importance of several proangiogenic factors in the prognosis of ovarian cancer, suggesting …

Background Angiogenesis is a critical component of tumor development and proliferation,
and increased angiogenesis has been associated with a worse clinical outcome in a …

Results of standard chemotherapy in ovarian cancer are hampered by the development of
drug resistance leading to disease recurrence. This prompted interest in the development of …

Ovarian carcinoma is the most important cause of gynaecological cancer-related mortality in
Western societies. The age at diagnosis, extent of disease (as expressed by FIGO state) …

Introduction: Ovarian cancer is the most lethal gynecological cancer, mainly because of the
advanced stage of the disease at diagnosis, with recent research investigating novel targets …